Summary
Previous investigations have suggested that hydrophilic β-Blockers, which appear at low concentrations in brain tissue, are less likely to produce CNS-related side-effects than are lipophilic β-Blockers, which occur at higher concentrations in the brain. The validity of this hypothesis was tested in a double-blind crossover study in which the hydrophilic β-blocker atenolol was compared with the lipophilic agents metoprolol and propranolol, in 14 patients with a previous history of nightmares or hallucinations when treated with lipophilic β-Blockers. Nightmares or hallucinations were reported by all patients receiving lipophilic β-Blockers but by only three patients receiving atenolol. The total number of episodes was significantly lower (p<0.01) for patients receiving atenolol (8) than for those receiving lipophilic β-Blockers (54). It is concluded that atenolol is significantly less likely to provoke nightmares and hallucinations than are the lipophilic β-Blockers, metoprolol and propranolol. It seems likely that this finding is due to the differences in hydrophilicity amongst these drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abel MJ, Longshaw S, Reeves P (1978) Imperial Chemical Industries Limited, Pharmaceuticals Division, Safety of Medicines Department.
Betts T (1982) VIIIth Scientific Meeting of the International Society of Hypertension. Mexico City
Cowen PJ, Graham-Smith DG, Green AR, Green DJ (1982) Beta-adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioural responses. Br J Pharmacol 76: 265–270
Cove-Smith R, Kirk CA (1983) Letter to the editor. Postgrad Med J 59 (Suppl 3): 161–163
Cruickshank JM, Neil-Dwyer G, Cameron MM, McAinsh J (1979) VIth Scientific Meeting of the International Society of Hypertension. Gothenburg
Cruickshank JM (1980) The clinical importance of cardioselectivity and lipophilicity in beta-blockers. Am Heart J 100: 160–178
Fraser HS, Carr AC (1976) Propranolol psychosis. Br J Psychiatry 129–508
Hallberg H, Almgren O, Svensson TS (1982) Reduced brain serotonergic activity after repeated treatment with beta-adrenoceptor antagonists. Psychopharmacology 76: 114–117
Hansson L, Åberg H, Karlberg BE, Westerlund A (1975) Controlled study of atenolol in treatment of hypertension. Br Med J 17: 367–370
Hansson L, Karlberg BE, Åberg H, Westerlund A, Jameson S, Henningsen NC (1976) Long-term hypotensive effect of atenolol (ICI 66 082) a new beta-adrenergic blocking agent. Acta Med Scand 199: 257–261
Mattiasson I, Henningsen NC (1978) VIIIth World Congress of Cardiology. Tokyo
Middlemiss DN, Blakeborough L, Leather SR (1977) Direct evidence for an interaction of beta-adrenergic blockers with the 5-HT receptor. Nature 267: 289–290
Myers MG, Lewis PJ, Reid JL, Dollery CT (1975) Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man. Pharmacol Exp Ther 192: 327
Svenson T (1982) Emerging aspects of the adrenergic nervous system. Acta Anaesth Scand 76: 8–11
Westerlund A (1983) A comparison of the central nervous system side effects caused by lipophilic and hydrophilic beta blockers. Drugs 2 (Suppl 25): 280–281
van Zweiten PA, Timmermans PBMWM (1979) Comparison between the acute hemodynamic effects and brain penetration of atenolol and metoprolol. J Cardiovasc Pharmacol 1: 85–96
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Westerlund, A. Central nervous system side-effects with hydrophilic and lipophilic β-Blockers. Eur J Clin Pharmacol 28 (Suppl 1), 73–76 (1985). https://doi.org/10.1007/BF00543714
Issue Date:
DOI: https://doi.org/10.1007/BF00543714